Table 1.
Clinicopathological description of the optimization and validation cohorts.
| Optimization cohort (n = 5 samples) | |
|---|---|
| Cases | Description |
| Sample #1 | 37 years, Seminoma, Stage I |
| Sample #2 | 28 years, Seminoma, Stage I |
| Sample #3 | 37 years, Embryonal carcinoma, Stage II |
| Sample #4 | 34 years, Embryonal carcinoma, stage III |
| Sample #5 | 44 years, healthy blood donor |
| Validation cohort summary (n= 107 samples) | |
| TGCT samples | 56 |
| Pre-orchiectomy | 31 |
| First follow-up timing | 15 |
| Second follow-up timing | 9 |
| Third follow-up timing | 1 |
| Non-TGCT testicular mass samples | 3 |
| Male healthy blood donors | 47 |
| Non-testicular tumor with elevated AFP (hepatocarcinoma) | 1 |
| TGCT patients—clinicopathological features | |
| Age (years [median, interquartile range]) | 33 (8.5) |
| Size of tumor mass (cm [mean, interquartile range]) | 5.7 (3.95) |
| Histology (n, %) | |
| Seminoma | 19/31 (61.3) |
| Embryonal carcinoma | 2/31 (6.5) |
| Mixed tumor | 9/31 (29.0) |
| Postpubertal-type yolk sac tumor | 1/31 (3.2) |
| Stage (n, %) | |
| I | 19/31 (61.3) |
| II | 6/31 (19.4) |
| III | 6/31 (19.4) |
| AFP positive (n, %) | 9/31 (29.0) |
| HCG positive (n, %) | 12/31 (38.7) |
| LDH positive (n, %) | 14/31 (45.2) |
| Either AFP or HCG or LDH positive (n, %) | 20/31 (64.5) |
AFP, alpha fetoprotein; HCG, human chorionic gonadotropin; LDH, lactate dehydrogenase.